Instrument Inactif

Communiqués InMed Pharmaceuticals Inc Canadian Securities Exchange

Actions

IN

CA4576371062

Recherche biotechnologique et médicale

Communiqués

07/07	InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4	NE
04/06	InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements	NE
19/05	INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders	BU
19/05	InMed Pharmaceuticals Amends Preferred Investment Options	NE
07/05	InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update	NE
27/04	InMed Pharmaceuticals Amends Preferred Investment Options	NE
27/03	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance	NE
23/03	InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program	NE
09/03	InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial	NE
06/03	InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline	NE
11/02	InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update	NE
18/12	InMed Announces Results of 2025 Annual General and Special Meeting	NE
12/12	InMed Provides Update on BayMedica Commercial Business	NE
18/11	InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901	NE
06/11	InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update	NE
24/10/25	InMed Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3)	PU
16/10/25	InMed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors	NE
09/10/25	InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors	NE
23/09/25	InMed Pharmaceuticals : Annual Report for Fiscal Year Ending June 30, 2025 (Form 10-K)	PU
23/09/25	InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update	NE
16/09/25	InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025	AQ
05/09/25	InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference	NE
28/07/25	InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025	NE
27/06/25	InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules	NE
25/06/25	InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules	NE